Description
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the Aβ peptide. It recognizes soluble monomeric, not fibrillar, Aβ. Solanezumab (formerly known as LY2062430) is a monoclonal antibody being developed by Lilly as a potential therapy for people with mild cognitive impairment caused by Alzheimer’s disease.
Catalog No.
DHC12505
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1.8 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
Research Grade Biosimilar
Target
AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P05067
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
LY2062430, CAS: 955085-14-0
Note
For research use only. Not suitable for clinical or therapeutic use.
關(guān)鍵字： DHC12505;AICD-57, A4;
武漢佰樂博生物（Biolab Reagents）始創(chuàng)于 2021 年，核心創(chuàng)始團(tuán)隊(duì)由五位畢業(yè)于武漢大學(xué)、華中科技大學(xué)、華中農(nóng)業(yè)大學(xué)等高校的生命科學(xué)領(lǐng)域頂尖研究者組成，團(tuán)隊(duì)深耕行業(yè)二十載，積淀了扎實(shí)的產(chǎn)品開發(fā)實(shí)力與技術(shù)應(yīng)用經(jīng)驗(yàn)，筑牢企業(yè)核心技術(shù)根基。
公司是國家高新技術(shù)企業(yè)、國家科技型中小企業(yè)，國家創(chuàng)新型中小企業(yè)，技術(shù)實(shí)力獲權(quán)威認(rèn)可，還通過 ISO9001、ISO13485 雙質(zhì)量管理體系認(rèn)證，以標(biāo)準(zhǔn)化品控筑牢產(chǎn)品品質(zhì)。依托全球領(lǐng)先技術(shù)平臺(tái)，公司專注高品質(zhì)生物試劑的全球化開發(fā)與整合，是法國 AntibodySystem 亞洲獨(dú)家授權(quán)合作伙伴以及生工生物KleanAB品牌的合作伙伴，現(xiàn)構(gòu)建起近 60000 種試劑的產(chǎn)品矩陣，核心涵蓋蛋白、抗體、試劑盒，重點(diǎn)覆蓋腫瘤、神經(jīng)系統(tǒng)，病原菌感染等疾病研究領(lǐng)域，滿足多元科研需求。
自成立以來，佰樂博生物始終為科研工作者、生物醫(yī)藥工業(yè)客戶提供專業(yè)的產(chǎn)品與技術(shù)支持，以優(yōu)質(zhì)科研工具賦能科研，助力生命科學(xué)研究創(chuàng)新發(fā)展、深度突破。